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International guidelines for ERBB2 (HER2) testing procedures in breast cancer patients highlight the importance of external
quality control. In contrast, internal quality assurance programs have been poorly deﬁned, and their clinical signiﬁcance has
not yet been investigated. We developed a quality assurance scheme by performing HER2 FISH on 724 patients randomly selected
out of 1996 patients with breast cancer presenting at our institute. We collected samples monthly for tissue microarray analysis
and correlated HER2 gene status with IHC scores. The concordance was excellent (κ = 0.92, P<0.0001). HER2 ampliﬁcation
characterized 25% of score 2+ but also 13% of score 1+, thus expanding the number of patients eligible for trastuzumab. Based on
these ﬁndings, the FISH test is now recommended at our institution for score 1+ and 2+ patients. Adherence to internal assurance
program improves patient selection and may lead to the deﬁnition of in-house tailored diagnostic algorithms diﬀerent from those
proposed in international guidelines.
1.Introduction
ERBB2 (commonly referred to as HER2) protein overex-
pression or gene ampliﬁcation is a predictive marker for
response to trastuzumab (Herceptin) in patients with breast
cancer (BC) [1, 2]. Immunohistochemistry (IHC) and ﬂuo-
rescence in situ hybridization (FISH) are the only tests
currently approved by the Federal Drug Administration
(FDA) and by the European Medicines Agency (EMA) for
HER2testing.Inclinicalpractice,patientsmaybeconsidered
eligible for treatment with trastuzumab if classiﬁed as score
3+ by IHC or if they carry gene ampliﬁcation as detected by
FISH. In contrast, patients showing score 0 or 1+ by IHC
or the absence of gene ampliﬁcation by FISH should not
be submitted to targeted therapy. The American Society of
Clinical Oncology and the College of American Pathologists
(ASCO/CAP) strongly recommend that patients with
equivocal results by IHC (i.e., score 2+) should be further
investigated by FISH to conﬁrm eligibility [3].
The importance of external quality proﬁciency assess-
ment for HER2 testing has been emphasized by the
ASCO/CAP and by the United Kingdom National External
Quality Assurance Scheme (UK-NEQAS) [4–6]. In contrast,
although strongly recommended by the ASCO/CAP, internal
quality assurance programs have been weakly deﬁned and
their clinical signiﬁcance has been poorly investigated. Thus,
the aim of this study was to develop a reliable and eﬀective
internal quality assurance scheme and to determine its in-
ﬂuence on patients management.
2.MaterialsandMethods
2.1. Patients. From January 2004 to December 2010, a total
of 1996 patients were diagnosed with breast cancer at the
Institute of Pathology, Locarno, Switzerland. Formalin-ﬁxed
paraﬃn-embedded(FFPE)tissuesamplesof998cases(50%)
were prospectively selected through a systematic random2 Pathology Research International
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1996 patients diagnosed with breast cancer
from 2004 to 2010
998 patients were prospectively
and randomly selected to set up an
internal quality assurance program
244 patients were selected by
pathologists to deﬁne eligibility
for trastuzumab treatment
736 cases had evaluable
HER2 FISH results
234 cases had evaluable
HER2 FISH results
724 cases had evaluable
HER2 IHC results
216 cases had evaluable
HER2 IHC results
Control series (TMA) Diagnostic series (FFPE)
Figure 1: Breast cancer patient selection chart.
sampling procedure (sampling interval = 2) and were used
to set up an in-house internal assurance system (Figure 1).
Tissue samples were collected monthly and included on
tissue microarrays (TMA). Every patient was punched twice
on TMA. Only cases for which at least one core was evaluable
were considered. 169 (17%) patients were excluded from the
study because of inadequate sampling on the TMA, such as
missing or insuﬃcient/detached tumor tissue, or presence of
necrosis. 93 (9%) patients were excluded due to inadequate
FISHresults(absenceorloweﬃciencyofhybridization,poor
signals quality, presence of autoﬂuorescence, and presence of
artifacts).
In 736 (74%) cases FISH analysis for HER2 was consid-
ered reliable. In 12 cases, data on HER2 protein expression as
determined by IHC were not available. Eventually, the “con-
trol series” consisted of 724 cases, corresponding to 36.3% of
the total number of patients with invasive breast cancer diag-
nosed over the observation period. The mean age of patients
was 63 years, the mean tumor size was 21.6mm, estrogen
receptor expression (deﬁned as more than 5% of positive
cells)wasdetectedin85%ofcases,andprogesteronereceptor
expression was detected in 70% of cases. The histotypes were
ductal(74.9%),lobular(10.4%),andother(14.7%).Thehis-
tological grade was well to moderately diﬀerentiated in 62%
and poorly diﬀerentiated in 38% of cases. Patient and tumor
characteristics were comparable to data obtained in a recent
population-basedstudyfromthesamegeographicalarea[7],
thus indicating that the control series was representative of
the general population living in our region.
We also investigated whole tissue samples of 244 breast
cancer patients that were selected by pathologists, on the
basisofambiguousornotrepresentativeimmunohistochem-
ical proﬁle, or by oncologists, on the basis of clinical features
and indications for trastuzumab treatment. Similarly to the
control series, we considered only patients for which both
FISH and IHC results were available (Figure 1). 10 (4%)
patients were excluded for unsuccessful FISH experiments
and 18 (7%) patients for not evaluable IHC staining.
Eventually, 216 cases were evaluated in this group, which was
referred to as the “diagnostic series.” Forty-seven cases from
this series were also included in the control series.
2.2. Construction of TMAs. TMAs were constructed as
described previously [8]. Every month, paraﬃn blocks used
for immunohistochemical analyses in the routine diagnoses
of breast cancers were selected through a systematic random
sampling procedure (sampling interval = 2) by technicians
unaware of clinical data and tumor characteristics and were
included on a TMA. For each patient, two representative
cores 0.6mm in diameter were punched. Each tumor array
contained samples of approximately 10 to 30 patients. As an
internal control, two previously characterized breast cancer
specimens were included in each TMA, one with and one
without HER2 gene ampliﬁcation.
2.3. Fluorescence In Situ Hybridization. FISH was performed
on 4μm thick sections of TMAs of the control series and
on whole FFPE tissue sections of the diagnostic series using
the FDA-approved LSI HER2/CEP17 probe set (PathVysion,
Abbott, Baar, Switzerland). Slides were treated according
to the manufacturer’s instructions. FISH was evaluated
according to the established g
uidelines and by calculating the ratio of HER2 signals to
CEP17 signals (R)[ 3]. Patients were stratiﬁed depending on
their HER2 gene status as ampliﬁed (R>2.2), not ampliﬁed
(R<1.8), and equivocal (1.8 <R<2.2).
2.4. Immunohistochemistry. I H Cw a sp e r f o r m e do n4 μm
thick FFPE tissue sections using the FDA-approved clonePathology Research International 3
Table 1: Results of HER2 protein status as determined by IHC and gene status as determined by FISH in breast cancer patients from the
control series.
FISH
Control series Not ampliﬁed Equivocal Ampliﬁed Total
IHC
0 471 97% 7 1% 7 1% 485 67%
1+ 51 85% 1 2% 8 13% 60 8%
2+ 33 65% 5 10% 13 25% 51 7%
3+ 3 2% 0 0% 125 98% 128 18%
total 558 77% 13 2% 153 21% 724 100%
Table 2: Results of HER2 protein status as determined by IHC and gene status as determined by FISH in breast cancer patients from the
diagnostic series.
FISH
Diagnostic series Not ampliﬁed Equivocal Ampliﬁed Total
IHC
0 22 100% 0 0% 0 0% 22 10%
1+ 30 77% 5 13% 4 10% 39 18%
2+ 82 61% 18 13% 34 25% 134 62%
3+ 0 0% 0 0% 21 100% 21 10%
total 134 62% 23 11% 59 27% 216 100%
CB11 (Novocastra, Newcastle upon Tyne, UK) according
to the manufacturer’s instructions, which were adapted to
an internal standardized protocol for automated staining
(Benchmark, Roche, Basel, Switzerland). Because HER2 IHC
is routinely performed on all BC samples obtained at our
institute, overexpression was evaluated on full FFPE tissue
sections in both the control series (on the original block
selected for TMA punching) and the diagnostic series. As
an internal control, a breast cancer specimen with a known
HER2 score 3+ was included on each histological slide
subjected to immunohistochemical analysis. Patients were
classiﬁed according to their HER2 protein staining as score
0, 1+, 2+, or 3+, according to well-established evaluation
criteria [3].
2.5. Concordance. Cohen’s kappa test (κ) was used to eval-
uate the concordance between the IHC and FISH results.
This rate was calculated considering negative cases, that is,
scores 0 and 1+ by IHC and no ampliﬁcation as determined
by FISH, and positive cases, that is, a score 3+ by IHC and
ampliﬁcationasdeterminedbyFISH.Patientswithequivocal
IHC or FISH results (score 2+ or equivocal) were not con-
sidered for this purpose. Concordance was assessed by Fleiss’
equally arbitrary guidelines, which characterize κ values over
0.75 as excellent, 0.40 to 0.75 as fair to good, and below 0.40
as poor [9]. All statistical tests were two-sided. Signiﬁcance
levelsweresetatP ≤ 0.05.Allstatisticalanalyseswerecarried
out using the SAS version 9.1 (SAS Institute Inc, Cary, NC).
3. Results
In the control series, 128 (18%) out of 724 patients were
classiﬁed as score 3+ by IHC, 51 (7%) patients as score 2+,
60 (8%) patients as score 1+, and 485 (67%) patients as
score 0 (see Table 1). Using FISH analysis, 153 (21%) out of
724 patients were classiﬁed as ampliﬁed, 13 (2%) patients as
equivocal, and 558 (77%) as not ampliﬁed (see Table 1). The
percentage of concordant results between IHC and FISH was
equal to 97.3%, with a statistically signiﬁcant κ value of 0.92
(P<0.0001).
Eighteen (2%) patients showed discordant HER2 protein
status as detected by IHC and HER2 gene status as detected
by FISH: 7/485 (1%) patients classiﬁed by IHC as score 0
and 8/60 (13%) patients classiﬁed as score 1+ showed gene
ampliﬁcation by FISH, whereas 3/128 (2%) patients with
score 3+ by IHC did not have HER2 gene ampliﬁcation. To
investigate the discrepancies for these 18 patients, all IHC
stainings were reevaluated, and FISH was repeated on whole
FFPE tissue sections. In 11 (61%) out of these 18 patients,
the discrepancy was due to pathologist error in scoring of
HER2 protein expression or of HER2 gene status, in 5 (28%)
cases, protein or genetic tumor heterogeneity was considered
to be the source of the disagreement between IHC and FISH,
and, in 2 (11%) patients, no reasons for the discrepancy were
found, as the FISH and IHC analyses were truly discordant.
Inthediagnosticseries,21(10%)outof216patientswere
classiﬁed as score 3+ by IHC, 134 (62%) patients as score
2+, 39 (18%) patients as score 1+, and 22 (10%) patients
as score 0 (see Table 2). Using FISH, 59 (27%) out of 216
patients were classiﬁed as ampliﬁed, 23 (11%) patients as
equivocal, and 134 (62%) as not ampliﬁed (see Table 2). The
percentage of concordant results between IHC and FISH was
equal to 94.8%, with a statistically signiﬁcant κ value of 0.88
(P<0.0001). The 4 (2%) discordant cases were classiﬁed as
score 1+ by IHC and showed gene ampliﬁcation by FISH.
Disagreement was due to tumor heterogeneity in 3 (75%)
patients and to an error in the scoring of the IHC staining
in one (25%) patient.4 Pathology Research International
Diﬀerences in the frequencies of the IHC and FISH
categoriesbetweenthecontrolseriesandthediagnosticseries
were related to the type of BC patients included in the two
cohorts (randomly selected patients versus patients selected
on demand). However, when grouping patients by HER2
FISH status, IHC scores between the two series overlapped
(Tables 1 and 2). As an example, considering FISH ampliﬁed
category in the control series and in the diagnostic series,
respectively, 0% and 1% of cases were classiﬁed as score 0,
13% and 10% were classiﬁed as score 1+, 25% and 25% were
classiﬁed as score 2+, and 98% and 100% were classiﬁed as
score 3+, thus demonstrating the high reproducibility of this
scheme at our institute.
4. Discussion
Accurate determination of HER2 status is essential for op-
timalpatientsselectionfortargettherapy.Testing procedures
follow international guidelines, and the importance of exter-
nal quality assurance programs has been widely recognized.
Experts propose two opposite work ﬂows: the use of the IHC
test for initial evaluation followed by FISH only on equivocal
cases(score2+)or,otherwise,theuseofFISHasthefrontline
assay [3, 4]. No gold standard exists currently, but it is gen-
erally accepted that the detection of gene ampliﬁcation by
FISH is more accurate and predictive for the response to
trastuzumabtherapyinbreastcancerpatients[4].Ithasbeen
suggested that performing FISH routinely as the initial test
is a cost-eﬀective approach, considering the therapeutic con-
textasawhole[4,10].Indailypractice,however,manypath-
ology laboratories still perform IHC as the frontline test be-
cause of technical aspects, cost, and economic issues related
to the Health Insurance System.
Internal quality assurance programs for HER2 testing
have been poorly deﬁned, and their signiﬁcance in the clini-
cal management of BC patients remains unknown. The
ASCO/CAP guidelines recommend initial validation proce-
dures before the test is oﬀered, ongoing biannual test valida-
tion, ongoing equipment maintenance, the use of standard-
ized operating protocols with the routine use of control mat-
erials, and ongoing education and training of laboratory per-
sonnel and pathologists [3].
To provide consistent and reproducible diagnostic re-
sults, we developed an internal quality assurance scheme by
performing HER2 FISH on a representative series of BC pa-
tients, randomly and prospectively included on TMAs, and
by correlating HER2 gene status with IHC scores. This ap-
proach is robust, cost-eﬀective, and not time-consuming. It
allows continuous monitoring of the concordance between
IHC and FISH and ongoing reciprocal controls for both
techniques.
Our laboratory follows the recommendation for HER2
testing mentioned above and formulated by the ASCO/CAP
[3]. In particular, optimal IHC and FISH testing require-
ments and optimal tissue handling requirements have been
implemented since 2005. Test validation assays have been
performed, and both IHC and FISH procedures are per-
formedusingappropriatepositiveandnegativecontrols.The
pathologists scoring the immunohistochemical staining and
the cytogeneticists reading the FISH results undergo ongoing
competence assessment and education. External quality
assurance programs were routinely carried out during the
study period (UK-NEQAS and others). Our laboratory has
been accredited since 2009 by the Swiss Accreditation System
(SAS) according to the ISO/IEC 17025 and ISO/IEC 15189
norms (STS 525). Nevertheless, the implementation of an
internal quality assurance scheme allowed us to modify the
diagnostic algorithm suggested by international guidelines
to identify patients eligible for trastuzumab. In fact, in our
series, 13% of patients considered negative by IHC testing
(i.e., score 1+) had HER2 gene ampliﬁcation. We therefore
advise clinicians referring to our laboratory to require FISH
as a predictive test not only in BC patients with IHC score 2+
but also in score 1+ patients. In contrast, we consider FISH
analysis of score 0 and score 3+ samples not to be useful.
There are at least two main reasons to explain the
“underperformance”ofIHCindetectingpatientswithHER2
ampliﬁcation in score 1+ cases. First, the standardization
of IHC tests remains sometimes problematic and may be
aﬀected by preanalytical and analytical factors [3]. Even
adherence to external quality assurance programs for IHC
HER2 testing may be not enough to obtain reproducible
results because, in contrast to ongoing internal quality
assurance scheme, such external programs pursue quality
control only sporadically. Furthermore, the results may be
biased by handling samples with awareness by laboratory
personnel and pathologists, thus not truly reﬂecting daily
work procedures. Second, our results underscore the well-
known poor reproducibility of the evaluation of semiquan-
titative immunohistochemical staining in equivocal cases
[3, 4]. In contrast, we do not think that the implementation
of validated IHC tests would have led to more precise
HER2 testing because the concordance between the “in-
house” results and FISH analysis was excellent. Furthermore,
externalqualitycontrolsofHER2testingbyIHCalwaysyield
positive feedback.
In conclusion, we strongly believe that an ongoing inter-
nal quality assurance program for HER2 testing improves
performance, reduces the frequency of inaccurate results,
and may have more clinical impact than sporadic external
quality controls. We suggest that pathology laboratories
should monitor HER2 testing continuously by correlating
IHC and FISH and that analysis of these data may lead to the
deﬁnition of in-house tailored diagnostic algorithms diﬀer-
ent from those proposed and recommended in the literature.
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